- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Abbott receives FDA approval for generic version of iopamidol
Abbott could drive contrast prices even lowerPrices for x-ray contrast media in the U.S. could go even lower in the next several months after healthcare giant Abbott Laboratories introduces its generic version of iopamidol. The Food and Drug
Abbott could drive contrast prices even lower
Prices for x-ray contrast media in the U.S. could go even lower in the next several months after healthcare giant Abbott Laboratories introduces its generic version of iopamidol. The Food and Drug Administration ruled in December that a version of iopamidol developed by the Abbott Park, IL, company is the generic equivalent of Isovue, a nonionic, low-osmolar x-ray contrast agent developed by Bracco of Milan, Italy.
The expiration of Bracco's U.S. patents on iopamidol has prompted consternation among established contrast agent companies like Bracco, Nycomed, and Mallinckrodt, because generic versions of iopamidol will compete with low-osmolar nonionic products from all companies. The arrival of generic iopamidol is believed to be one of the factors behind the ongoing slump in prices for contrast agents, and the drop has prompted several contrast companies to seek mergers with other firms to reduce their reliance on the x-ray market.
Abbott is only one of several companies developing generic versions of iopamidol, with other potential competitors including ESI-Lederle, Hovione of Portugal, Faulding Pharmaceutical, and Brightstone Pharma. Faulding received FDA approval for its version of iopamidol in 1996 (SCAN 12/18/96).
Abbott's introduction of iopamidol could have the biggest impact on the market, however, due to the company's extensive distribution network. Abbott's small army of field sales representatives are already calling on hospitals regarding other products, and it should be relatively easy for the company to insert generic iopamidol into its product offerings. The company is planning to begin selling the product some time this spring, an Abbott spokesperson said.
Iopamidol will also round out Abbott's expanding product portfolio. The company already offers MRI and x-ray contrast agents it has accessed through an agreement signed in 1996 with Schering subsidiary Berlex Laboratories (SCAN 7/3/96). Abbott also has rights to EchoGen, an ultrasound contrast agent under development by Sonus Pharmaceuticals that is expected to be close to FDA approval.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
